NovoCure (NVCR) Receivables - Net (2014 - 2026)

NovoCure (NVCR) has reported Receivables - Net for 13 consecutive years, with $99.1 million the latest figure, recorded in Q2 2026.

• Quarterly Receivables - Net rose 10.25% year-over-year to $99.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $99.1 million (up 10.25% YoY) and the FY2025 annual result came in at $89.4 million, up 20.49% from the prior year.
• Receivables - Net advanced to $99.1 million in Q2 2026 per NVCR's latest filing, from $93.3 million in the prior quarter.
• Over the last five years, Receivables - Net for NVCR reached as high as $101.0 million in Q1 2022 and fell as low as $22.7 million in Q4 2023.
• A 5-year average of $73.3 million and a median of $79.7 million in 2023 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net sank 72.26% — and 2025, when it jumped 155.07%.
• Year by year, Receivables - Net stood at $26.0 million in 2022, then slipped by 12.64% to $22.7 million in 2023, then surged by 54.62% to $35.1 million in 2024, then soared by 155.07% to $89.4 million in 2025, then rose by 10.84% to $99.1 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $99.1 million, $93.3 million, and $89.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.